It is a pharma private limited company based in Delhi, Delhi, India, established in 1996.
1996 | Delhi, Delhi, India | ActiveF-Seven Pharmaceutical Private Limited, a active private limited company, was established on 14 February 1996 in Delhi, Delhi, India. Engaging in pharmaceutical retailers & distributors within the financial and insurance service sector, it holds CIN: U33112DL1996PTC076314. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹4.50 M and a paid-up capital of ₹4.11 M.
It upholds a compliant status. Its leadership includes Nitin Aggarwal (Director), Suresh Kumar Aggarwal (Director), Mayank Aggarwal (Director). Past directors included Sourabh Bansal, Nitin Aggarwal, Roshan Lal. It holds ₹5.00 Cr open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 154, 1St Floor Aggarwal Cyber Plaza-1, Plot No-C-4,5,6, Netaji Subhash Place, Pitampura, Delhi, Delhi, 110034.
U33112DL1996PTC076314
076314
14 February 1996
₹4.50 M
₹4.11 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into F-Seven Pharmaceutical Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nitin Aggarwal | Director | 10 Jun 2024 | Current |
| Suresh Kumar Aggarwal | Director | 20 Jan 2014 | Current |
| Mayank Aggarwal | Director | 20 Jan 2014 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 25 Jan 2014 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2024 | Past |
| Pramod Abcsdd | Director | 25 Jan 2014 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2015 | Past |
| Pramod Abcsdd | Director | 06 Aug 2007 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2014 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
F-Seven Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.36% increase. The company also saw a substantial improvement in profitability, with a 13.93% increase in profit. The company's net worth moved up by a moderate rise of 3.18%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, F-Seven Pharmaceutical had a promoter holding of 65.73% and a public holding of 34.27%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹50,000,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Nov 2024 | Others | ₹5.00 Cr | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with F-Seven Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of F-Seven Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped F-Seven Pharmaceutical's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity A charge with Others amounted to Rs. 50.00 M with Charge ID 101020063 was registered on 30 Nov 2024. was completed.
Progress on F-Seven Pharmaceutical Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
Progress on Nitin Aggarwal was appointed as a Director was appointed as a Director on 10 Jun 2024 & has been associated with this company since 1 year 5 months . was documented.
F-Seven Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was recorded as a recent event.
Suresh Kumar Aggarwal was appointed as a Director was appointed as a Director on 20 Jan 2014 & has been associated with this company since 11 years 10 months . was recorded as a recent event.
Mayank Aggarwal was appointed as a Director was appointed as a Director on 20 Jan 2014 & has been associated with this company since 11 years 10 months . was recorded as a recent event.
The CIN of F-Seven Pharmaceutical Private Limited is U33112DL1996PTC076314.
F-Seven Pharmaceutical Private Limited is headquartered at 154, 1St Floor Aggarwal Cyber Plaza-1, Plot No-C-4,5,6, Netaji Subhash Place, Pitampura, Delhi, Delhi, 110034.
F-Seven Pharmaceutical Private Limited was incorporated on 14 February 1996.
The current directors of F-Seven Pharmaceutical Private Limited are
The primary industry of F-Seven Pharmaceutical Private Limited is Financial And Insurance Service.
F-Seven Pharmaceutical Private Limited is unlisted.
The authorized capital of F-Seven Pharmaceutical Private Limited is ₹4.50 M, and the paid-up capital is ₹4.11 M.
The compliance status of F-Seven Pharmaceutical Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX